Healthcare / Drug Manufacturers - Specialty & GenericKSE
$11130.00
-10.00 (-0.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $29.3B · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$172.3B
P/E
6.0x
↓EV/EBITDA
4.1x
↓ROE
13.0%
↑Gross Margin
28.0%
↓Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.9%
FCF CAGR
+66.8%
FCF margin
10.5%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $257.83B · net income $28.61B · FCF $27.10B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $257.83B | $257.83B | $222.48B | $206.86B | $188.93B |
| Net Income | $28.61B | $28.61B | $43.99B | $28.14B | $14.96B |
| EBITDA | $52.78B | $52.78B | $76.82B | $51.93B | $38.83B |
| EPS | 1847.00 | 1847.00 | 2841.00 | 1818.00 | 966.00 |
| Gross Margin | 28.0% | 28.0% | 25.8% | 25.3% | 25.5% |
| Operating Margin | 12.9% | 12.9% | 16.1% | 14.9% | 14.3% |
| Net Margin | 11.1% | 11.1% | 19.8% | 13.6% | 7.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.35 | 0.29 | 0.48 |
| Current Ratio | 1.09 | 1.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $27.10B | $27.10B | $40.38B | $29.31B | $5.84B |
| Returns | |||||
| ROE | 13.0% | 13.0% | 21.9% | 17.7% | 10.7% |
| Valuation | |||||
| P/E | 6.03 | 6.03 | 3.85 | 7.02 | 12.06 |
| EV/EBITDA | 4.07 | 4.07 | 3.01 | 4.31 | 6.28 |
| P/B | 0.78 | 0.78 | 0.84 | 1.24 | 1.29 |
| Growth & Yield | |||||
| Revenue Growth | 15.9% | 15.9% | 7.5% | 9.5% | — |
| EPS Growth | -35.0% | -35.0% | 56.3% | 88.2% | — |
| Dividend Yield | 4.9% | 4.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-18.8%
EPS terminal req.
$987.60
Spread vs growth
-16.2%
5Y implied EPS CAGR
-8.3%
EPS terminal req.
$1195.00
Spread vs growth
-26.6%
10Y implied EPS CAGR
0.4%
EPS terminal req.
$1924.56
Spread vs growth
-35.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.8%
Start / end P/E
4.2x → 6.0x
EPS bridge
2841.00 → 1847.00
Residual
-15.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.